Creo Medical Group (LON:CREO) Shares Down 12.4% – Here’s What Happened

Posted by Patrick Bannon on Oct 2nd, 2026

Creo Medical Group PLC (LON:CREO – Get Free Report) shares traded down 12.4% on Wednesday. The stock traded as low as GBX 9.90 and last traded at GBX 10.40. Approximately 7,994,368 shares traded hands during trading, an increase of 921% from the average session volume of 783,030 shares. The stock had previously closed at GBX 11.88.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price objective on shares of Creo Medical Group in a report on Thursday, July 23rd.

Read Our Latest Analysis on CREO

Creo Medical Group Price Performance

The company has a 50-day moving average of GBX 12.62 and a 200 day moving average of GBX 12.82. The company has a quick ratio of 2.19, a current ratio of 2.79 and a debt-to-equity ratio of 8.09. The stock has a market capitalization of £47.61 million, a PE ratio of 9.80 and a beta of 1.56.

Creo Medical Group (LON:CREO – Get Free Report) last announced its quarterly earnings data on Wednesday, September 30th. The company reported GBX (2) earnings per share for the quarter. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%. Sell-side analysts predict that Creo Medical Group PLC will post -10.0800005 EPS for the current year.

Creo Medical Group Company Profile

(Get Free Report)

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.